Sung Lee

CFO Sung Lee sells 38,730 CYTK shares ($3.2M) via 10b5-1 plan; retains 63,221 shares plus 162,228 option shares

Sung Lee, EVP and CFO of Cytokinetics, executed a scheduled 10b5-1 sale of 38,730 shares at $82.30 on 2026-06-24, reducing non-derivative holdings by 38.0% from 101,951 to 63,221 shares. However, this partial reduction occurs alongside substantial derivative holdings of 162,228 option shares across seven vehicles, indicating the insider retains meaningful upside exposure to the company. The stock has appreciated 13.7% over 30 days and 32.4% over 90 days from the transaction date, trading near the 52-week high of $87.35. While the company achieved remarkable 376.6% annual revenue growth, it remains unprofitable with full-year net income of $-206.0M, creating a contrast between top-line momentum and current earnings profile that warrants monitoring as the business scales.

CFO Lee Sung sells ~$1.84M in CYTK stock—substantial position reduction amid unprofitable operations and weak recent price momentum.

Lee Sung, Cytokinetics' Chief Financial Officer, sold approximately 27% of his holdings in a single transaction, generating $1.84 million in proceeds. The timing is notable: the stock is currently trading slightly below its recent highs but still well above its annual lows, and over the past month it has shown minimal downward pressure. However, the company's underlying fundamentals present a concerning picture—the business is unprofitable with a substantial annual net loss, and recent revenue figures suggest significant year-over-year contraction. When a C-suite executive of an unprofitable company exits a meaningful portion of their stake, it warrants attention, especially when the stock's price strength might otherwise mask financial deterioration. The sale appears deliberate and material enough to signal caution, though it does not constitute an emergency signal; this is a CFO managing personal wealth at a company burning cash, not a catastrophic red flag.